Improving drug penetration to curb tumor drug resistance

Drug Discovery Today

Volumn 17, Issue 19-20, 2012, Pages 1139-1146

  Marcucci, Fabrizio ^a,b   Corti, Angelo ^c  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Hepatology Association of Calabria   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ASSOCIATION; CANCER PATIENT; CELL ADHESION; CELL INTERACTION; CYTOTOXICITY; DRUG ACCUMULATION; DRUG PENETRATION; DRUG RESISTANCE; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; IMMUNE RESPONSE; NONHUMAN; OVERALL SURVIVAL; OXYGENATION; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIOTHERAPY; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG RESISTANCE; HUMANS; NEOPLASMS; PHARMACOKINETICS;

EID: 84866742980     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.06.004     Document Type: Review

References (87)

1. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
2. R.K. Jain Determinants of tumor blood flow: a review Cancer Res. 48 1988 2641 2658
3. A.I. Mitchinton, and I.F. Tannock Drug penetration in solid tumors Nat. Rev. Cancer 6 2006 583 592
4. H. Hashizume Openings between defective endothelial cells explain tumor vessel leakiness Am. J. Pathol. 156 2000 1363 1380
5. A.J. Leu Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation Cancer Res. 60 2000 4324 4327
6. H. Maeda Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects Bioconjugate Chem. 21 2010 797 802
7. M.E. O'Brien Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15 2004 440 449
8. F. Marcucci, and F. Lefoulon Active targeting with particulate drug carriers: fundamentals and recent progress Drug Discov. Today 9 2004 219 228
9. M. Montana Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers J. Chemother. 23 2011 59 66
10. I.F. Tannock Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy Clin. Cancer Res. 8 2002 878 884
11. F. Marcucci, and A. Corti How to improve exposure of tumor cells to drugs - promoter drugs increase tumor uptake and penetration of effector drugs Adv. Drug Deliv. Rev. 64 2012 53 68
12. A. Nagamitsu Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors Jpn. J. Clin. Oncol. 39 2009 756 766
13. R.J. Buckanovich Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy Nat. Med. 14 2008 28 36
14. D.F. Emerich Bradykinin modulation of tumor vasculature: I. Activation of B2 receptors increases delivery of chemotherapeutic agents into solid peripheral tumors, enhancing their efficacy J. Pharmacol. Exp. Ther. 296 2001 623 631
15. I. Lee Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications Cancer Res. 52 1992 3237 3240
16. H. Hurwitz Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335 2342
17. S. Ning Anti-αv integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats Cancer Res. 70 2010 7591 7599
18. V. Gregorc Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors Clin. Cancer Res. 17 2011 1964 1972
19. L.A. Khawli NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy Clin. Cancer Res. 11 2005 3084 3093
20. Y. Morinaga Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo Cancer Sci. 94 2003 200 204
21. S. Strieth Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with cisplatin Clin. Cancer Res. 14 2008 4601 4603
22. C.G. Willett Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat. Med. 10 2004 145 147
23. F. Curnis Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) Nat. Biotechnol. 18 2000 1185 1190
24. F. Curnis Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration J. Clin. Invest. 110 2002 475 482
25. A. Corti Targeted drug delivery and penetration into solid tumors Med. Res. Rev. 2011 10.1002/med.20238 (Epub ahead of print)
26. I. Beyer Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer Cancer Res. 71 2011 7080 7090
27. G. Griffon-Etienne Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors Cancer Res. 59 1999 3776 3782
28. K.P. Olive Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461
29. B. Diop-Frimpong Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors Proc. Natl. Acad. Sci. U. S. A. 108 2011 2909 2914
30. L. Eikenes Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts Br. J. Cancer 93 2005 81 88
31. J. Lankelma Doxorubicin gradients in human breast cancer Clin. Cancer Res. 5 1999 1703 1707
32. O. Trédan Drug resistance and the solid tumor microenvironment J. Natl. Cancer Inst. 99 2007 1441 1454
33. R.C. Jackson The problem of the quiescent cancer cell Adv. Enzyme Regul. 29 1989 27 46
34. F. Winkler Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563
35. G.M. Thurber Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance Adv. Drug Deliv. Rev. 60 2008 1421 1434
36. C.L. Vogel Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast J. Clin. Oncol. 20 2002 719 726
37. S.I. Rudnick Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors Cancer Res. 71 2011 2250 2259
38. A. Musolino Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer J. Clin. Oncol. 26 2008 1789 1796
39. T.T. Junttila Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer Cancer Res. 70 2010 4481 4489
40. A. Sacchi Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-α Clin. Cancer Res. 12 2006 175 182
41. K.N. Sugahara Co-administration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Science 328 2010 1031 1035
42. Q. Huang Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy Nat. Med. 17 2011 860 866
43. Z.C. Hartmann HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis Cancer Res. 71 2011 4380 4391
44. V. Levina Chemotherapeutic drugs and human tumor cells cytokine network Int. J. Cancer 123 2008 2031 2040
45. B. Bauer Tumor necrosis factor α and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier Mol. Pharmacol. 71 2007 667 675
46. D. Conze Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells Cancer Res. 61 2001 8851 8858
47. D.G. Duda CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin. Cancer Res. 17 2011 2074 2080
48. L. Levati Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB Int. J. Oncol. 38 2011 241 247
49. S. Ponnusamy Sphingolipids and cancer: ceramide and sphingosine-1- phosphate in the regulation of cell death and drug resistance Future Oncol. 6 2010 1603 1624
50. Y. Guo Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer Clin. Cancer Res. 16 2010 5759 5769
51. A. Gougelet Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody PLoS ONE 4 2009 e8026
52. S.A. Hunsucker Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma Br. J. Haematol. 152 2011 579 592
53. K.A.D. Sauter Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome Cancer Biol. Ther. 11 2011 1008 1016
54. L.A. Gilbert, and M.T. Hemann Chemotherapeutic resistance: surviving stressful situations Cancer Res. 71 2011 5062 5066
55. P. Kaler Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1β-dependent stabilization of Snail in tumor cells PLoS ONE 5 2010 e11700
56. J. Huang HMGB1 promotes drug resistance in osteosarcoma Cancer Res. 72 2012 230 238
57. W. Huang HMGB1, a potent proinflammatory cytokine in sepsis Cytokine 51 2010 119 126
58. G.P. Sims HMGB1 and RAGE in inflammation and cancer Annu. Rev. Immunol. 28 2010 367 388
59. L. Pusztai Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy Cytokine 25 2004 94 102
60. C-H. Heldin High interstitial fluid pressure - an obstacle in cancer therapy Nat. Rev. Cancer 4 2004 806 813
61. T.P. Padera Cancer cells compress intratumor vessels Nature 427 2004 695
62. G. Cheng Micro-environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells PLoS ONE 4 2009 e4632
63. G. Helmlinger Solid stress inhibits the growth of multicellular tumor spheroids Nat. Biotechnol. 15 1997 778 783
64. C. Koike Solid stress facilitates spheroid formation: potential involvement of hyaluronan Br. J. Cancer 86 2002 947 953
65. J. Yang Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis Cell 117 2004 927 939
66. J.M. Tse Mechanical compression drives cancer cells toward invasive phenotype Proc. Natl. Acad. Sci. U. S. A. 109 2012 911 916
67. R.M. Sappington, and D.J. Calkins Contribution of TRPV1 to microglia-derived IL-6 and NF-κB translocation with elevated hydrostatic pressure Invest. Ophthalmol. Vis. Sci. 49 2008 3004 3017
68. K. Takahashi Hydrostatic pressure induces expression of interleukin 6 and tumour necrosis factor α mRNAs in a chondrocyte-like cell line Ann. Rheum. Dis. 57 1998 231 236
69. D. Graetz High ICP as trigger of proinflammatory IL-6 cytokine activation in aneurysmal subarachnoid hemorrhage Neurol. Res. 32 2010 728 735
70. R.M. Sappington, and D.J. Calkins Pressure-induced regulation of IL-6 in retinal glial cells: involvement of the ubiquitin/proteasome pathway and NFkappaB Invest. Ophthalmol. Vis. Sci. 47 2006 3860 3869
71. Z. Yao TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer Proc. Natl. Acad. Sci. U. S. A. 107 2010 15535 15540
72. D. Iliopoulos Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion Proc. Natl. Acad. Sci. U. S. A. 108 2011 1397 1402
73. M.B. Meads Environment-mediated drug resistance: a major contributor to minimal residual disease Nat. Rev. Cancer 9 2009 665 674
74. N. Cordes β1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury Oncogene 25 2006 1378 1390
75. S. Sebens Mürköster Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells Oncogene 26 2007 2759 2768
76. R. Fridman Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines Proc. Natl. Acad. Sci. U. S. A. 87 1990 6698 6702
77. Y. Mori Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis Blood 104 2004 2149 2154
78. C.C. Park Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo Cancer Res. 66 2006 1526 1535
79. C.C. Park Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts Cancer Res. 68 2008 4398 4405
80. C. Brekken Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase Anticancer Res. 20 2000 3503 3512
81. M. Sonnenberg Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast BMC Cancer 8 2008 364
82. R. De Souza Chemotherapy dosing schedule influences drug resistance development in ovarian cancer Mol. Cancer Ther. 10 2011 1289 1299
83. E. Pasquier Metronomic chemotherapy: new rationale for new directions Nat. Rev. Clin. Oncol. 7 2010 455 465
84. R. Munoz Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy Cancer Res. 66 2006 3386 3391
85. S. Dellapasqua Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer J. Clin. Oncol. 26 2008 4899 4905
86. G. Allegrini A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients Br. J. Cancer 98 2008 1312 1319
87. C.G. Willett Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a Phase I trial in rectal cancer patients J. Clin. Oncol. 23 2005 8136 8139